RE: COLLABORATION DEALS4 Oct 2025 18:06
Q/A is 1 yr old, but the answer is as relevant today as it was then:
Transcription of Investor Meet Avacta Presentation 30.09.2024 Q/A session
CC responding to questions.
Question 1:
Avacta has told shareholders we have been in deal-value discussions since June 2023. The data has improved at every juncture. When will the company finally deliver on the multiple promises made over the past year and announce a license deal.
Answer 1
We have been working hard on this over the last few months. We – the management team - have met many companies, US, Europe, Asia.
There’s generally a lot of interest in Avacta and our platform, which has enabled us to have these multiple conversations.
We have still early data in our Phase 1 trial with 57 patients treated.
We should also remember why we are interested in such deals / collaborations.
There are two reasons, the first is validation from well-known players in the oncology space, and second secure some upfront non-dilutive funding.
Recall the amount of funding received in the form of upfront payment to execute on the deal is going to be based on the stage of the deal and the asset, so for example a pre-clinical deal with another company’s medicine and the precision technology won’t be worth near to what an asset with phase 2 data would be worth.
We have spoken to a number of smaller and mid-sized biotech’s who can move very quickly and are interested to collaborate at an early stage, but whilst we could do some deals with these types of companies, often they are not going to give us the validation that we would really like.
To be honest we may even help them more in this respect than they help us as the medicine would be in their pipeline.
Their ability to provide meaningful funding is somewhat limited.
We have also spoken to large pharma companies which would partner entire assets or for example AVA6000 and can provide the validation we are interested in, as well as the meaningful financial terms, but these larger pharmaceutical companies tend to work very slowly, - want more data, with these types of deals, and we really do require data into phase two, a defined patient population with a defined objective response rate, progression free survival, you know multiple end points and we’re just not there yet.
We’re continuing to have these conversations and we continue the work here deal making at least among several of the players.
The ADC space has also cooled just a bit as there have been multiple phase three failures here, so it’s really important for us to consider the external factors as well.
We will have further conversations planned but we also very much want to set the expectation.
We won't strike a deal for the sake of striking a deal, where we don’t feel we are getting the right validation or the funding the technology really deserves.
Sign In
Follow the stocks
